xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06008093</url>
    </required_header>
    <id_info>
      <org_study_id>D419ML00003</org_study_id>
      <nct_id>NCT06008093</nct_id>
    </id_info>
    <brief_title>A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
    <acronym>TRITON</acronym>
    <official_title>A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>AstraZeneca</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>AstraZeneca</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>Yes</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in&#xD;
        combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in&#xD;
        metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations&#xD;
        in STK11, KEAP1, or KRAS.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        A trial to learn if durvalumab plus tremelimumab with chemotherapy is safe and how well it&#xD;
        works compared to pembrolizumab with chemotherapy in participants with metastatic non-small&#xD;
        cell lung cancer with certain genetic mutations.&#xD;
  &#xD;
        INFORMATION FOR TRIAL PARTICIPANTS:&#xD;
  &#xD;
        Researchers are looking for a better way to treat people who have metastatic NSCLC and tumors&#xD;
        with STK11, KEAP1, or KRAS genetic mutations. Most people learn they have NSCLC after it has&#xD;
        already become metastatic, and it can no longer be treated with surgery.&#xD;
  &#xD;
        Based on previous trials, researchers think durvalumab plus tremelimumab with chemotherapy&#xD;
        could help participants more than the current standard treatment, which is pembrolizumab with&#xD;
        chemotherapy. Durvalumab and tremelimumab are designed to work by helping the immune system&#xD;
        recognize and kill cancer cells.&#xD;
  &#xD;
        In this trial, researchers want to learn more about how well durvalumab plus tremelimumab&#xD;
        with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause&#xD;
        the cancer to be less responsive to treatment.&#xD;
  &#xD;
        This trial is planned to have 280 participants. These participants will be randomly divided&#xD;
        into one of two groups:&#xD;
  &#xD;
          -  One group will receive durvalumab plus tremelimumab with chemotherapy&#xD;
  &#xD;
          -  One group will receive pembrolizumab with chemotherapy&#xD;
  &#xD;
        Durvalumab, tremelimumab, pembrolizumab, and chemotherapy are given as an injection over time&#xD;
        into a vein, also called an IV infusion. Chemotherapy will be one of the following regimens:&#xD;
        pemetrexed plus cisplatin or pemetrexed plus carboplatin.&#xD;
  &#xD;
        This is an open-label trial. This means that each participant will know which trial treatment&#xD;
        they receive, and the doctors and trial staff will also know.&#xD;
  &#xD;
        Researchers will measure and compare:&#xD;
  &#xD;
          -  How long participants live during the trial&#xD;
  &#xD;
          -  How long participants live during the trial without their cancer getting worse&#xD;
  &#xD;
          -  How many participants' tumors respond to treatment&#xD;
  &#xD;
          -  How long participants' tumor responses last&#xD;
  &#xD;
          -  How long before participants need to start a different treatment type&#xD;
  &#xD;
        Researchers will also keep track of all the medical problems participants have during the&#xD;
        trial and monitor their safety.&#xD;
  &#xD;
        Participants will be in this trial for up to approximately 4 years. They will stop receiving&#xD;
        trial treatment if they no longer benefit from it or they stop participating for another&#xD;
        reason.&#xD;
  &#xD;
        Participants will visit their trial site every 3 to 4 weeks. At most visits, participants&#xD;
        will:&#xD;
  &#xD;
          -  Have a physical exam and answer questions about any medications they are taking or any&#xD;
             medical problems they have&#xD;
  &#xD;
          -  Receive their trial treatment&#xD;
  &#xD;
          -  Give blood and urine samples&#xD;
  &#xD;
          -  Have pictures of their tumors taken using CT or MRI scans&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 16, 2023</start_date>
    <completion_date type="Anticipated">October 22, 2031</completion_date>
    <primary_completion_date type="Anticipated">November 30, 2026</primary_completion_date>
    <phase>Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Phase IIIb 2-arm, parallel randomized open label multicenter study</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Overall survival (OS)</measure>
      <time_frame>From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause in all participants.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>OS in subset of randomized participants with STK11 or KEAP1 mutations and/or co-mutations</measure>
      <time_frame>From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause in participants with STK11 or KEAP1 mutations and/or co-mutations.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 12 months</measure>
      <time_frame>At 12 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 24 months</measure>
      <time_frame>At 24 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 12 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations.</measure>
      <time_frame>At 12 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 24 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations.</measure>
      <time_frame>At 24 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival in subset of randomized participants whose PD-L1 status is PD-L1 TC &lt; 1%</measure>
      <time_frame>From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 12 months in subset of randomized participants whose PD-L1 status is PD-L1 TC &lt; 1%</measure>
      <time_frame>At 12 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival at 24 months in subset of randomized participants whose PD-L1 status is PD-L1 TC &lt; 1%</measure>
      <time_frame>At 24 months</time_frame>
      <description>OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Progression-free survival (PFS)</measure>
      <time_frame>From randomization until disease progression, death, withdrawal of consent, or end of study (approximately 48 months)</time_frame>
      <description>PFS is defined as the time from randomization until the date of confirmed PD (per Response Evaluation Criteria in Solid Tumours, Version 1.1 [RECIST 1.1] as assessed by the Investigator) or death due to any cause (in the absence of progression) in all participants.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Objective response rate (ORR)</measure>
      <time_frame>From randomization until disease progression, or the last evaluable assessment in the absence of progression (approximately 48 months)</time_frame>
      <description>ORR is defined as the proportion of participants with a confirmed objective tumour response (complete response [CR] or partial response [PR]) as determined by the investigator per RECIST 1.1 in all participants who have measurable disease at baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Duration of response (DOR)</measure>
      <time_frame>From first documented response until documented progression (approximately 48 months)</time_frame>
      <description>DOR is defined as the time from the date of first documented confirmed response until the date of documented progression (per RECIST 1.1, as assessed by the Investigator) or death due to any cause (in the absence of disease progression) in all participants who have confirmed objective response.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time to First Subsequent Therapy (TFST)</measure>
      <time_frame>From randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention or death [approx. up to 48 months]</time_frame>
      <description>TFST is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention, or death due to any cause in all participants.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs).</measure>
      <time_frame>From screening until the follow-up period is completed [approx. up to 48 months]</time_frame>
      <description>To assess the safety and tolerability of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in participants with non-squamous histology who have metastatic NSCLC with mutations and/or co-mutations in STK11, KEAP1, or KRAS.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">280</enrollment>
    <condition>Carcinoma, Non-Small-Cell Lung</condition>
    <arm_group>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive durvalumab plus tremelimumab q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until disease progression or unacceptable toxicity or treatment discontinuation. During the maintenance therapy phase, participants will receive an additional cycle of durvalumab plus tremelimumab (plus pemetrexed, where applicable) at Week 16.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Arm B: Pembrolizumab + Platinum-based Chemotherapy</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (pembrolizumab plus pemetrexed maintenance) q3w until disease progression or unacceptable toxicity for up to 24 months or treatment discontinuation.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Durvalumab</intervention_name>
      <description>Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.</description>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Tremelimumab</intervention_name>
      <description>Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.</description>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Pemetrexed</intervention_name>
      <description>Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.</description>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
      <other_name>Background Platinum-based Chemotherapy</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Pembrolizumab</intervention_name>
      <description>Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.</description>
      <arm_group_label>Arm B: Pembrolizumab + Platinum-based Chemotherapy</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Carboplatin</intervention_name>
      <description>Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.</description>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
      <arm_group_label>Arm B: Pembrolizumab + Platinum-based Chemotherapy</arm_group_label>
      <other_name>Background Platinum-based Chemotherapy</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Cisplatin</intervention_name>
      <description>Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.</description>
      <arm_group_label>Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy</arm_group_label>
      <arm_group_label>Arm B: Pembrolizumab + Platinum-based Chemotherapy</arm_group_label>
      <other_name>Background Platinum-based Chemotherapy</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Pemetrexed</intervention_name>
      <description>Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.</description>
      <arm_group_label>Arm B: Pembrolizumab + Platinum-based Chemotherapy</arm_group_label>
      <other_name>Background Platinum-based Chemotherapy</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Histologically or cytologically documented Stage IV non-squamous NSCLC not amenable to&#xD;
               curative surgery or radiation.&#xD;
  &#xD;
            -  Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are&#xD;
               also allowed.&#xD;
  &#xD;
            -  Participants must have tumors that lack activating epidermal growth factor receptor&#xD;
               mutations and ALK fusions.&#xD;
  &#xD;
            -  No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Participants&#xD;
               who have received prior platinum-containing adjuvant, neoadjuvant, or definitive&#xD;
               chemoradiation for advanced disease are eligible, provided that progression has&#xD;
               occurred &gt; 6 months from end of last therapy.&#xD;
  &#xD;
            -  No prior exposure to immune-mediated therapy excluding therapeutic anti-cancer&#xD;
               vaccines, within 12 months to randomization.&#xD;
  &#xD;
            -  WHO/ECOG performance status of 0 or 1 at enrollment and randomization.&#xD;
  &#xD;
            -  Minimum life expectancy ≥ 12 weeks at randomization.&#xD;
  &#xD;
            -  At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target&#xD;
               lesion at baseline and can be accurately measured at baseline as ≥ 10 mm in the&#xD;
               longest diameter with Computed Tomography (CT)/CT- Positron Emission Tomography or&#xD;
               Magnetic Resonance Imaging and that is suitable for accurate repeated measurements as&#xD;
               per RECIST 1.1 guidelines.&#xD;
  &#xD;
            -  Adequate organ and bone marrow function:&#xD;
  &#xD;
            -  Negative pregnancy test (urine or serum) for women of child-bearing potential&#xD;
  &#xD;
            -  Female participants must be 1 year post-menopausal, surgically sterile, or using one&#xD;
               highly effective form of birth control&#xD;
  &#xD;
            -  Male and Female participants and their partners must use an acceptable method of&#xD;
               contraception.&#xD;
  &#xD;
            -  Body weight of &gt; 30 kg&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Any evidence of acute or uncontrolled diseases or history of allogeneic organ&#xD;
               transplant.&#xD;
  &#xD;
            -  Mixed small cell lung cancer and NSCLC histology.&#xD;
  &#xD;
            -  Major surgical procedure within 28 days prior to the first dose of the study&#xD;
               intervention or an anticipated need for major surgery during the study.&#xD;
  &#xD;
            -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
               inflammatory bowel disease [eg, colitis or Crohn's disease], systemic lupus&#xD;
               erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease,&#xD;
               rheumatoid arthritis [requiring immunosuppressive systemic therapy, eg, methotrexate,&#xD;
               steroids], hypophysitis, uveitis, etc), autoimmune pneumonitis and autoimmune&#xD;
               myocarditis. The following are exceptions to this criterion:&#xD;
  &#xD;
                 -  Participants with vitiligo or alopecia.&#xD;
  &#xD;
                 -  Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on&#xD;
                    hormone replacement.&#xD;
  &#xD;
                 -  Any chronic skin condition that does not require systemic therapy.&#xD;
  &#xD;
                 -  Participants without active disease in the last 5 years may be included but only&#xD;
                    after consultation with the Study Clinical Lead.&#xD;
  &#xD;
                 -  Participants with celiac disease controlled by diet alone.&#xD;
  &#xD;
            -  Medical contraindication to platinum-based doublet chemotherapy.&#xD;
  &#xD;
            -  History of another primary malignancy except:&#xD;
  &#xD;
                 -  Malignancy treated with curative intent with no known active disease ≥ 2 years&#xD;
                    before the first dose of study intervention and of low potential risk for&#xD;
                    recurrence&#xD;
  &#xD;
                 -  Adequately resected non-melanoma skin cancer and curatively treated in situ&#xD;
                    disease.&#xD;
  &#xD;
            -  Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥&#xD;
               2) caused by previous anti-cancer therapy, alopecia and vitiligo are excluded&#xD;
               toxicities.&#xD;
  &#xD;
            -  Participants with Grade ≤ 2 neuropathy can be considered based on Investigator's&#xD;
               judgement. Participants with irreversible toxicity that is not reasonably expected to&#xD;
               be exacerbated by treatment with study intervention in the opinion of the Investigator&#xD;
               may be included (eg, hearing loss).&#xD;
  &#xD;
            -  Spinal cord compression unless asymptomatic and stable.&#xD;
  &#xD;
            -  Participant meets the following:&#xD;
  &#xD;
               - Symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac&#xD;
               arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy,&#xD;
               ventricular tachycardia), which requires treatment (CTCAE Grade 3), symptomatic or&#xD;
               uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained&#xD;
               ventricular tachycardia. Participants with atrial fibrillation controlled by&#xD;
               medication or arrhythmias controlled by pacemakers may be permitted based on the&#xD;
               Investigator judgement with cardiologist consultation recommended.&#xD;
  &#xD;
            -  Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy&#xD;
               for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related&#xD;
               conditions (eg, hormone replacement therapy) is acceptable.&#xD;
  &#xD;
            -  No radiation therapy is allowed, unless it is 1) definitive radiation that had been&#xD;
               administered at least 6 months prior, 2) palliative radiation to brain, with&#xD;
               associated criteria for stability or lack of symptoms, or 3) palliative radiation to&#xD;
               painful bony lesions (this must comprise less than 30% of the bone marrow)&#xD;
  &#xD;
            -  Patients with suspected brain metastases at screening should have an intravenous (IV)&#xD;
               contrast-enhanced MRI (preferred) or IV contrast-enhanced CT/CT-PET of the brain prior&#xD;
               to study entry. If brain metastases are detected patients must be treated before&#xD;
               randomization. Randomization is only permitted if patients with brain metastases have:&#xD;
  &#xD;
                 -  Confirmed stable condition&#xD;
  &#xD;
                 -  Returned neurologically to baseline Brain metastases will not be recorded as&#xD;
                    RECIST target lesions at baseline.&#xD;
  &#xD;
            -  History of leptomeningeal carcinomatosis.&#xD;
  &#xD;
            -  Known to have tested positive for active tuberculosis infection&#xD;
  &#xD;
            -  Known active hepatitis infection, positive HCV antibody, HBsAg, or anti-HBc, at&#xD;
               screening. Participants with a past or resolved HBV infection (defined as the presence&#xD;
               of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody&#xD;
               are eligible only if PCR is negative for HCV RNA. Participants co-infected with HBV&#xD;
               and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg&#xD;
               and/or anti-HBcAb with detectable HBV DNA); AND&#xD;
  &#xD;
                 -  HCV positive (presence of anti-HCV antibodies); OR&#xD;
  &#xD;
                 -  HDV positive (presence of anti-HDV antibodies).&#xD;
  &#xD;
            -  Known human immunodeficiency virus (HIV) infection that is not well controlled.&#xD;
  &#xD;
            -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
               dose of study intervention. The following are exceptions to this criterion:&#xD;
  &#xD;
                 -  Intranasal, inhaled, topical steroids or local steroid injections (eg,&#xD;
                    intra-articular injection).&#xD;
  &#xD;
                 -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                    prednisone or its equivalent.&#xD;
  &#xD;
                 -  Steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
                    premedication, premedication for chemotherapy) or a single dose for palliative&#xD;
                    purpose (eg, pain control).&#xD;
  &#xD;
            -  Receipt of live attenuated vaccine within 30 days prior to the first dose of study&#xD;
               intervention.&#xD;
  &#xD;
            -  Concurrent enrollment in another clinical study, unless it is an observational&#xD;
               (non-interventional) clinical study or the follow-up period of an interventional&#xD;
               study.&#xD;
  &#xD;
            -  Participants with a known hypersensitivity to any of the study interventions or any of&#xD;
               the excipients of the products.&#xD;
  &#xD;
            -  For females only: Currently pregnant (confirmed with positive pregnancy test) or&#xD;
               breast-feeding, or who are planning to become pregnant.&#xD;
  &#xD;
          Female participants should refrain from breastfeeding from enrolment throughout the study&#xD;
          and until up to 14 months after the last dose of cisplatin or 180 days after pemetrexed or&#xD;
          90 days after tremelimumab or durvalumab or pembrolizumab, whichever is longer; and during&#xD;
          treatment with carboplatin.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>130 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>AstraZeneca Clinical Study Information Center</last_name>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </overall_contact>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 23, 2023</study_first_posted>
    <last_update_submitted>August 17, 2023</last_update_submitted>
    <last_update_submitted_qc>August 17, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 23, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Mutation</keyword>
    <keyword>Metastatic Non-Small Cell Lung Cancer</keyword>
    <keyword>Kelch-Like ECH-Associated Protein 1 (KEAP1)</keyword>
    <keyword>Kirsten rat sarcoma virus (KRAS)</keyword>
    <keyword>Programmed death-ligand 1 (PD-L1)</keyword>
    <keyword>Serine/threonine kinase 11 (STK11)</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lung Neoplasms</mesh_term>
      <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Carboplatin</mesh_term>
      <mesh_term>Pembrolizumab</mesh_term>
      <mesh_term>Pemetrexed</mesh_term>
      <mesh_term>Durvalumab</mesh_term>
      <mesh_term>Tremelimumab</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:&#xD;
  https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. &quot;Yes&quot;, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
      <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
      <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.</ipd_access_criteria>
      <ipd_url>https://vivli.org/</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06008093
  org study id: D419ML00003
  nct id: NCT06008093
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  is us export: Yes
  The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in
        combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in
        metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations
        in STK11, KEAP1, or KRAS.
  A trial to learn if durvalumab plus tremelimumab with chemotherapy is safe and how well it
        works compared to pembrolizumab with chemotherapy in participants with metastatic non-small
        cell lung cancer with certain genetic mutations.
  
        INFORMATION FOR TRIAL PARTICIPANTS:
  
        Researchers are looking for a better way to treat people who have metastatic NSCLC and tumors
        with STK11, KEAP1, or KRAS genetic mutations. Most people learn they have NSCLC after it has
        already become metastatic, and it can no longer be treated with surgery.
  
        Based on previous trials, researchers think durvalumab plus tremelimumab with chemotherapy
        could help participants more than the current standard treatment, which is pembrolizumab with
        chemotherapy. Durvalumab and tremelimumab are designed to work by helping the immune system
        recognize and kill cancer cells.
  
        In this trial, researchers want to learn more about how well durvalumab plus tremelimumab
        with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause
        the cancer to be less responsive to treatment.
  
        This trial is planned to have 280 participants. These participants will be randomly divided
        into one of two groups:
  
          -  One group will receive durvalumab plus tremelimumab with chemotherapy
  
          -  One group will receive pembrolizumab with chemotherapy
  
        Durvalumab, tremelimumab, pembrolizumab, and chemotherapy are given as an injection over time
        into a vein, also called an IV infusion. Chemotherapy will be one of the following regimens:
        pemetrexed plus cisplatin or pemetrexed plus carboplatin.
  
        This is an open-label trial. This means that each participant will know which trial treatment
        they receive, and the doctors and trial staff will also know.
  
        Researchers will measure and compare:
  
          -  How long participants live during the trial
  
          -  How long participants live during the trial without their cancer getting worse
  
          -  How many participants' tumors respond to treatment
  
          -  How long participants' tumor responses last
  
          -  How long before participants need to start a different treatment type
  
        Researchers will also keep track of all the medical problems participants have during the
        trial and monitor their safety.
  
        Participants will be in this trial for up to approximately 4 years. They will stop receiving
        trial treatment if they no longer benefit from it or they stop participating for another
        reason.
  
        Participants will visit their trial site every 3 to 4 weeks. At most visits, participants
        will:
  
          -  Have a physical exam and answer questions about any medications they are taking or any
             medical problems they have
  
          -  Receive their trial treatment
  
          -  Give blood and urine samples
  
          -  Have pictures of their tumors taken using CT or MRI scans
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Phase IIIb 2-arm, parallel randomized open label multicenter study
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Overall survival (OS)
  time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
  description: OS is defined as the time from randomization until death due to any cause in all participants.
  measure: OS in subset of randomized participants with STK11 or KEAP1 mutations and/or co-mutations
  time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
  description: OS is defined as the time from randomization until death due to any cause in participants with STK11 or KEAP1 mutations and/or co-mutations.
  measure: Overall survival at 12 months
  time frame: At 12 months
  description: OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.
  measure: Overall survival at 24 months
  time frame: At 24 months
  description: OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.
  measure: Overall survival at 12 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations.
  time frame: At 12 months
  description: OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.
  measure: Overall survival at 24 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations.
  time frame: At 24 months
  description: OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.
  measure: Overall survival in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1%
  time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
  description: OS is defined as the time from randomization until death due to any cause.
  measure: Overall survival at 12 months in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1%
  time frame: At 12 months
  description: OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark.
  measure: Overall survival at 24 months in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1%
  time frame: At 24 months
  description: OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark.
  measure: Progression-free survival (PFS)
  time frame: From randomization until disease progression, death, withdrawal of consent, or end of study (approximately 48 months)
  description: PFS is defined as the time from randomization until the date of confirmed PD (per Response Evaluation Criteria in Solid Tumours, Version 1.1 [RECIST 1.1] as assessed by the Investigator) or death due to any cause (in the absence of progression) in all participants.
  measure: Objective response rate (ORR)
  time frame: From randomization until disease progression, or the last evaluable assessment in the absence of progression (approximately 48 months)
  description: ORR is defined as the proportion of participants with a confirmed objective tumour response (complete response [CR] or partial response [PR]) as determined by the investigator per RECIST 1.1 in all participants who have measurable disease at baseline.
  measure: Duration of response (DOR)
  time frame: From first documented response until documented progression (approximately 48 months)
  description: DOR is defined as the time from the date of first documented confirmed response until the date of documented progression (per RECIST 1.1, as assessed by the Investigator) or death due to any cause (in the absence of disease progression) in all participants who have confirmed objective response.
  measure: Time to First Subsequent Therapy (TFST)
  time frame: From randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention or death [approx. up to 48 months]
  description: TFST is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention, or death due to any cause in all participants.
  measure: Number of participants with adverse events (AEs) and serious adverse events (SAEs).
  time frame: From screening until the follow-up period is completed [approx. up to 48 months]
  description: To assess the safety and tolerability of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in participants with non-squamous histology who have metastatic NSCLC with mutations and/or co-mutations in STK11, KEAP1, or KRAS.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  arm group type: Experimental
  description: Participants will receive durvalumab plus tremelimumab q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until disease progression or unacceptable toxicity or treatment discontinuation. During the maintenance therapy phase, participants will receive an additional cycle of durvalumab plus tremelimumab (plus pemetrexed, where applicable) at Week 16.
  arm group label: Arm B: Pembrolizumab + Platinum-based Chemotherapy
  arm group type: Experimental
  description: Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (pembrolizumab plus pemetrexed maintenance) q3w until disease progression or unacceptable toxicity for up to 24 months or treatment discontinuation.
  intervention type: Drug
  intervention name: Durvalumab
  description: Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Tremelimumab
  description: Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Pemetrexed
  description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  other name: Background Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Pembrolizumab
  description: Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
  arm group label: Arm B: Pembrolizumab + Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Carboplatin
  description: Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  arm group label: Arm B: Pembrolizumab + Platinum-based Chemotherapy
  other name: Background Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Cisplatin
  description: Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.
  arm group label: Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy
  arm group label: Arm B: Pembrolizumab + Platinum-based Chemotherapy
  other name: Background Platinum-based Chemotherapy
  intervention type: Drug
  intervention name: Pemetrexed
  description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
  arm group label: Arm B: Pembrolizumab + Platinum-based Chemotherapy
  other name: Background Platinum-based Chemotherapy
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 130 Years
  healthy volunteers: No
  last name: AstraZeneca Clinical Study Information Center
  phone: 1-877-240-9479
  email: information.center@astrazeneca.com
  responsible party type: Sponsor
  mesh term: Lung Neoplasms
  mesh term: Carcinoma, Non-Small-Cell Lung
  mesh term: Carboplatin
  mesh term: Pembrolizumab
  mesh term: Pemetrexed
  mesh term: Durvalumab
  mesh term: Tremelimumab
  sharing ipd: Yes
  ipd description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
  https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
  ipd info type: Study Protocol
  ipd info type: Statistical Analysis Plan (SAP)
  ipd time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
  ipd access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
  ipd url: https://vivli.org/